Gowning Practices Provide Clues to cGMP Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gowning Practices Provide Clues to cGMP Compliance
Review gowning practices as a tool to evaluate cGMP compliance in a facility.


Pharmaceutical Technology
Volume 37, Issue 6, pp. 50-51
DANLEAP/GETTY IMAGES

The foundation of any successful quality-assurance system is strict adherence to good manufacturing practices (GMPs). Quality must be built into the design of a facility to ensure that drugs are manufactured under conditions and practices required by the GMP regulations. This concept is broadly embraced across the globe and promulgated by drug regulatory agencies, such as FDA in the United States, the European Medicines Agency in the European Union, and the World Health Organization, whose drug regulations are often used by developing countries and individual countries (e.g., China, India, and Brazil).

This principle is further enhanced by the practice of being current. FDA explains the idea of “current” as follows:

…the “c” in cGMP stands for “current,” requiring companies to use technologies and systems that are up-to-date in order to comply with the regulations. Systems and equipment that may have been “top-of-the-line” to prevent contamination, mix-ups, and errors 10 or 20 years ago may be less than adequate by today’s standards (1).

In a new facility, the expectation is that the design successfully embodies cGMPs. In existing legacy facilities and as buildings age, however, ensuring compliance with cGMPs is more complicated. A review of a facility’s gowning operations can bring significant insight into the current state of cGMP compliance.

Gowning embodies many of the major elements of cGMPs and as such is a window into a facility’s cGMPs. A highly compliant facility will have gowning operations that are clearly defined and readily understood (see Figure 1). Such operations are easy to diagram, easy to describe, and easy to apply consistently. Conversely, confusing, complicated, or highly individualized gowning operations are indicative of a facility with compliance issues. When gowning procedures are not simple or when there is a lack of consistency and gowning exceptions are allowed, a red flag should be raised and a detailed review of the facility undertaken.

Figure 1: Gowning process-flow diagram (courtesy of the author).

Because gowning is integral to a facility’s operation and reflects many of the fundamental aspects of cGMPs, an initial evaluation of a facility can be conducted by analyzing where and how gowning occurs. The following are three major gowning characteristics to look for.

Centralized vs. decentralized
Is gowning centralized or decentralized? Centralized gowning, occurring as part of the entry to a specific production area, although not a guarantee, is indicative of organized and orderly production zones. For centralization, functions of the same cleanliness grade must be grouped together and not dispersed into individualized or isolated islands of production. Centralized gowning is also indicative of organized material and personnel flows. If activities of one hygiene type are aggregated together, materials and personnel only need enter the zone once to have access to all the functions within. This can be contrasted with decentralized zones that require material and personnel to enter and exit production areas multiple times in the course of processing a single batch. Operational time is wasted on excessive material handling and multiple gowning/de-gowning sequences.

Appropriate gowning
Is the protective clothing appropriate for the cleanliness level of the area? In production areas designed to be classified as controlled environments (i.e., designed using ISO 14644-1 or Annex 1 of the EU GMPs [Manufacture of Sterile Medicinal Products]), the greatest source of contamination is the people working in the space. The clothing requirements must provide the amount of protection commensurate to the type of product processed, the operation being undertaken, and the cleanliness class or grade of the space.

We’ve seen facilities, for example, where primary and secondary packaging are combined and have only a single gowning access. As a consequence, secondary packaging must be maintained at the same high level of cleanliness that is required for primary packaging. In these facilities, the flow of materials for both primary and secondary share the same routing and result in intermixing of raw and in-process materials as well as primary and secondary packaging components. In this example, the easily identified misapplication of gowning reveals a larger GMP issue of confused and disorganized material handling. In addition, always gowning to the higher level increases operating costs in terms of gowning materials used and operational time.

Gowning inconsistency
Do you see gowned personnel walking outside their production areas? There are older facilities where the delineation between production and controlled non-classified areas is not strictly drawn. If gowned and un-gowned personnel are walking past each other in the same hallway, this is a significant problem. Problems that can be surmised about such a facility include:

  • Gowning is not centralized and time is wasted entering and exiting production suites.
  • Functional areas and hygiene zones are not organized for greatest operational effectiveness.
  • Flows are not unidirectional, resulting in raw and in-process materials routinely crossing paths.
  • The risk of mix-up and cross contamination is heightened.
  • There is an excessive amount of standard operating procedures.
  • Air-handling units are not efficiently designed or operated.

Although efficient air-handling units are not strictly a GMP issue, like all the other issues enumerated, these operational inefficiencies are reflected in a higher than necessary cost of goods. In air handling, for example, an economy of scale, duct layout, and energy usage is realized when functions of a single cleanliness zone are clustered together.

RELATED CONTENT

Trends in GMP Violations: A Q&A with FDA's Brian Hasselbach

GMP Compliance Becomes Prominent Enforcement Issue

More GMPs/Validation Topics

Questions to ask
To evaluate a facility, consider asking the following questions about the facility’s gowning operations:

  • Is the gowning operation easy to diagram?
  • Is the hierarchy of gowning simple and clear?
  • Is the hierarchy of gowning sequential relative to air classifications or grades?
  • Is there clear and complete segregation of types of gowning?
  • Are there exceptions to gowning protocols?
  • What do gowned personnel do when they go to the restrooms?
  • What do gowned personnel do when they go to the cafeteria?
  • Do you need to gown and de-gown just to get to a desired destination?

Regulatory guidelines for GMPs include straightforward statements, but the application of cGMPs to a facility is not so simple nor is it obvious. Because gowning is deeply integrated into a facility’s operation, many cGMP fundamentals are reflected in gowning implementation. These questions can be used to help conduct a simple, initial evaluation and to gain a better understanding of compliance issues in a facility. The result will reveal where a facility is compliant and where there is room for improvement.  Either finding will enable proceeding from a basis of knowledge and moving forward with confidence and a clear goal for maintaining compliance.

Reference
1. FDA, “Facts About Current Good Manufacturing Practices (cGMPs),” accessed Feb. 28, 2014.

Eric Bohn

About the Author
Eric Bohn is partner at Jacobs Wyper Architects, 1232 Chancellor St., Philadelphia, PA 19107,  tel: 215.985.0400, www.jacobswyper.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here